A citation-based method for searching scientific literature

Jeffrey J Raizer, Sean A Grimm, Alfred Rademaker, James P Chandler, Kenji Muro, Irene Helenowski, Laurie Rice, Katie McCarthy, Sandra K Johnston, Maciej M Mrugala, Marc Chamberlain. J Neurooncol 2014
Times Cited: 61







List of co-cited articles
591 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
Thomas J Kaley, Patrick Wen, David Schiff, Keith Ligon, Sam Haidar, Sasan Karimi, Andrew B Lassman, Craig P Nolan, Lisa M DeAngelis, Igor Gavrilovic,[...]. Neuro Oncol 2015
143
80

Atypical and anaplastic meningiomas treated with bevacizumab.
Lakshmi Nayak, Fabio M Iwamoto, Jeremy D Rudnick, Andrew D Norden, Eudocia Quant Lee, Jan Drappatz, Antonio Omuro, Thomas J Kaley. J Neurooncol 2012
110
52

Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.
Emil Lou, Ashley L Sumrall, Scott Turner, Katherine B Peters, Annick Desjardins, James J Vredenburgh, Roger E McLendon, James E Herndon, Frances McSherry, Julie Norfleet,[...]. J Neurooncol 2012
114
52

Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
Andrew D Norden, Jeffrey J Raizer, Lauren E Abrey, Kathleen R Lamborn, Andrew B Lassman, Susan M Chang, W K Alfred Yung, Mark R Gilbert, Howard A Fine, Minesh Mehta,[...]. J Neurooncol 2010
108
49

Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
Patrick Y Wen, W K Alfred Yung, Kathleen R Lamborn, Andrew D Norden, Timothy F Cloughesy, Lauren E Abrey, Howard A Fine, Susan M Chang, H Ian Robins, Karen Fink,[...]. Neuro Oncol 2009
90
44

Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review.
Thomas Kaley, Igor Barani, Marc Chamberlain, Michael McDermott, Katherine Panageas, Jeffrey Raizer, Leland Rogers, David Schiff, Michael Vogelbaum, Damien Weber,[...]. Neuro Oncol 2014
126
42

Temozolomide for treatment-resistant recurrent meningioma.
Marc C Chamberlain, Denice D Tsao-Wei, Susan Groshen. Neurology 2004
101
39

Recurrent meningioma: salvage therapy with long-acting somatostatin analogue.
Marc C Chamberlain, Michael J Glantz, Camilo E Fadul. Neurology 2007
121
37

Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.
Victoria E Clark, E Zeynep Erson-Omay, Akdes Serin, Jun Yin, Justin Cotney, Koray Ozduman, Timuçin Avşar, Jie Li, Phillip B Murray, Octavian Henegariu,[...]. Science 2013
496
37

Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005.
Yongli Ji, Cathryn Rankin, Steven Grunberg, Andy E Sherrod, Jamshid Ahmadi, Jeannette J Townsend, Lynn G Feun, Ruth K Fredericks, Christy A Russell, Fairooz F Kabbinavar,[...]. J Clin Oncol 2015
65
36

Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.
Priscilla K Brastianos, Peleg M Horowitz, Sandro Santagata, Robert T Jones, Aaron McKenna, Gad Getz, Keith L Ligon, Emanuele Palescandolo, Paul Van Hummelen, Matthew D Ducar,[...]. Nat Genet 2013
383
34

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
Andrew D Norden, Keith L Ligon, Samantha N Hammond, Alona Muzikansky, David A Reardon, Thomas J Kaley, Tracy T Batchelor, Scott R Plotkin, Jeffrey J Raizer, Eric T Wong,[...]. Neurology 2015
51
41


A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma.
Kent C Shih, Sajeel Chowdhary, Paul Rosenblatt, Alva B Weir, Gregg C Shepard, Jeffrey T Williams, Mythili Shastry, Howard A Burris, John D Hainsworth. J Neurooncol 2016
52
36

Salvage chemotherapy with CPT-11 for recurrent meningioma.
Marc C Chamberlain, Denice D Tsao-Wei, Susan Groshen. J Neurooncol 2006
64
29



Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
David A Reardon, Andrew D Norden, Annick Desjardins, James J Vredenburgh, James E Herndon, April Coan, John H Sampson, Sridharan Gururangan, Katherine B Peters, Roger E McLendon,[...]. J Neurooncol 2012
49
34

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Guido Reifenberger, Andreas von Deimling, Dominique Figarella-Branger, Webster K Cavenee, Hiroko Ohgaki, Otmar D Wiestler, Paul Kleihues, David W Ellison. Acta Neuropathol 2016
27

The 2007 WHO classification of tumours of the central nervous system.
David N Louis, Hiroko Ohgaki, Otmar D Wiestler, Webster K Cavenee, Peter C Burger, Anne Jouvet, Bernd W Scheithauer, Paul Kleihues. Acta Neuropathol 2007
26

Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy.
Marta Simó, Andreas A Argyriou, Miquel Macià, Gerard Plans, Carles Majós, Noemi Vidal, Miguel Gil, Jordi Bruna. Cancer Chemother Pharmacol 2014
40
40

Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma.
Warren P Mason, Fred Gentili, David R Macdonald, Subramanian Hariharan, Charlene R Cruz, Lauren E Abrey. J Neurosurg 2002
104
24

Trabectedin has promising antineoplastic activity in high-grade meningioma.
Matthias Preusser, Sabine Spiegl-Kreinecker, Daniela Lötsch, Adelheid Wöhrer, Maria Schmook, Karin Dieckmann, Walter Saringer, Christine Marosi, Walter Berger. Cancer 2012
43
34


Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
Malak Abedalthagafi, Wenya Linda Bi, Ayal A Aizer, Parker H Merrill, Ryan Brewster, Pankaj K Agarwalla, Marc L Listewnik, Dora Dias-Santagata, Aaron R Thorner, Paul Van Hummelen,[...]. Neuro Oncol 2016
154
24

DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.
Felix Sahm, Daniel Schrimpf, Damian Stichel, David T W Jones, Thomas Hielscher, Sebastian Schefzyk, Konstantin Okonechnikov, Christian Koelsche, David E Reuss, David Capper,[...]. Lancet Oncol 2017
341
24

Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma.
Steven M Grunberg, Martin H Weiss, Christy A Russell, Irving M Spitz, Jamshid Ahmadi, Alfredo Sadun, Regine Sitruk-Ware. Cancer Invest 2006
108
22

Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.
U M Schrell, M G Rittig, M Anders, U H Koch, R Marschalek, F Kiesewetter, R Fahlbusch. J Neurosurg 1997
132
22

A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study.
J W Goodwin, J Crowley, H J Eyre, B Stafford, K A Jaeckle, J J Townsend. J Neurooncol 1993
98
22

The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B.
S E Kaba, F DeMonte, J M Bruner, A P Kyritsis, K A Jaeckle, V Levin, W K Yung. Neurosurgery 1997
95
22

Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma.
Julia Furtner, Veronika Schöpf, Katharina Seystahl, Emilie Le Rhun, Roberta Rudà, Ulrich Roelcke, Susanne Koeppen, Anna Sophie Berghoff, Christine Marosi, Paul Clement,[...]. Neuro Oncol 2016
36
38

Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review.
Leland Rogers, Igor Barani, Marc Chamberlain, Thomas J Kaley, Michael McDermott, Jeffrey Raizer, David Schiff, Damien C Weber, Patrick Y Wen, Michael A Vogelbaum. J Neurosurg 2015
311
22

EANO guidelines for the diagnosis and treatment of meningiomas.
Roland Goldbrunner, Giuseppe Minniti, Matthias Preusser, Michael D Jenkinson, Kita Sallabanda, Emmanuel Houdart, Andreas von Deimling, Pantelis Stavrinou, Florence Lefranc, Morten Lund-Johansen,[...]. Lancet Oncol 2016
390
22

Bevacizumab-induced regression of anaplastic meningioma.
M J A Puchner, V H Hans, A Harati, F Lohmann, M Glas, U Herrlinger. Ann Oncol 2010
52
25

Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma.
Derek R Johnson, David W Kimmel, Patrick A Burch, Terrence L Cascino, Caterina Giannini, Wenting Wu, Jan C Buckner. Neuro Oncol 2011
52
25

TERT Promoter Mutations and Risk of Recurrence in Meningioma.
Felix Sahm, Daniel Schrimpf, Adriana Olar, Christian Koelsche, David Reuss, Juliane Bissel, Annekathrin Kratz, David Capper, Sebastian Schefzyk, Thomas Hielscher,[...]. J Natl Cancer Inst 2015
194
21

Epidemiology and etiology of meningioma.
Joseph Wiemels, Margaret Wrensch, Elizabeth B Claus. J Neurooncol 2010
598
21


Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients.
Fabio P Nunes, Vanessa L Merker, Dominique Jennings, Paul A Caruso, Emmanuelle di Tomaso, Alona Muzikansky, Fred G Barker, Anat Stemmer-Rachamimov, Scott R Plotkin. PLoS One 2013
61
19

mTORC1 inhibitors suppress meningioma growth in mouse models.
Doreen Pachow, Nadine Andrae, Nadine Kliese, Frank Angenstein, Oliver Stork, Annette Wilisch-Neumann, Elmar Kirches, Christian Mawrin. Clin Cancer Res 2013
70
19


Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Elena Mazza, Alba Brandes, Silvia Zanon, Marika Eoli, Giuseppe Lombardi, Marina Faedi, Enrico Franceschi, Michele Reni. Cancer Chemother Pharmacol 2016
23
52

Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation.
Manish K Aghi, Bob S Carter, Garth R Cosgrove, Robert G Ojemann, Sepideh Amin-Hanjani, Robert L Martuza, William T Curry, Fred G Barker. Neurosurgery 2009
308
18

Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab.
S Goutagny, E Raymond, O Sterkers, J M Colombani, M Kalamarides. Ann Oncol 2011
39
28

Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography.
C Muhr, O Gudjonsson, A Lilja, M Hartman, Z J Zhang, B Långström. Clin Cancer Res 2001
43
23

Non-resectable slow-growing meningiomas treated by hydroxyurea.
David Loven, Ruth Hardoff, Zvi Bar Sever, Adam P Steinmetz, Michael Gornish, Zvi H Rappaport, Eyal Fenig, Zvi Ram, Aaron Sulkes. J Neurooncol 2004
59
16



NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
Marianne F James, Sangyeul Han, Carolyn Polizzano, Scott R Plotkin, Brendan D Manning, Anat O Stemmer-Rachamimov, James F Gusella, Vijaya Ramesh. Mol Cell Biol 2009
189
16

Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations.
David E Reuss, Rosario M Piro, David T W Jones, Matthias Simon, Ralf Ketter, Marcel Kool, Albert Becker, Felix Sahm, Stefan Pusch, Jochen Meyer,[...]. Acta Neuropathol 2013
149
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.